Seoul National University Hospital
Seoul, South Korea
Location status: Recruiting
Location contact
Ho Young Hwang, MD, PhD
CONTACT
Suk Ho Sohn, MD
CONTACT
NCT Number: NCT05704296
Left internal thoracic artery (LITA) has been acknowledged as the first graft of choice for coronary artery bypass grafting (CABG). However, it is still not conclusive which one is the best second graft of choice among right internal thoracic artery, radial artery, right gastroepiploic artery, saphenous vein, and etc., as well as its configuration for CABG.
In our institution, saphenous vein has been primarily used for the second graft and we have harvested it with 'No touch technique'. We have been demonstrated the excellent long-term patency of this 'No touch saphenous vein' in many studies. However, it is still unknown which configuration is the better strategy for the saphenous vein as a Y-composite graft based on the left internal thoracic artery versus an aortocoronary conduit. Thus, we aimed to evaluate morphologic change of saphenous vein graft by 1-year intravascular ultrasound (IVUS) study and angiographic patency results between Y-composite graft and aortocoronary conduit.
Interested in participating?
Request Info19 year and older
All sexes
Interventional
Not applicable
Seoul, South Korea
Location status: Recruiting
Ho Young Hwang, MD, PhD
CONTACT
Suk Ho Sohn, MD
CONTACT
The enrolled patient underwent routine sternotomy, and left internal thoracic artery (LITA) and saphenous vein (SV) are harvested. After harvest, the patient is randomized to Y-composite group or aortocoronary group.
For Y-composite group, SV is anastomosed to LITA as Y-composite fashion. Then, LITA is anastomosed to left anterior descending artery. SV is anastomosed to the rest of the target vessels with sequential anastomosis technique (e.g. diagonal branch, obtuse marginal branch, posterolateral branch and posterior descending artery).
For aortocoronary group, LITA is anastomosed to left anterior descending artery. Then, SV is anastomosed to ascending aorta using proximal anastomosis assist device without clamping the aorta. SV is anastomosed to the rest of the target vessels with sequential anastomosis technique (e.g. diagonal branch, obtuse marginal branch, posterolateral branch and posteriori descending artery).
At 1-year follow-up, coronary angiography is performed to evaluate the patency of the saphenous vein graft. Clinical outcomes are also evaluated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Saphenous vein is used as a Y-composite graft during coronary artery bypass grafting
Saphenous vein is used as an aortocoronary graft during coronary artery bypass grafting
Time frame: at postoperative 1 year
Graft patency measured by coronary angiography
Time frame: at postoperative 1 year
all deaths from any cause
Time frame: at postoperative 1 year
Any death related to cardiac events, including sudden death during follow-up
Time frame: at postoperative 1 year
Intervention performed for the previously bypassed target vessel during follow-up
Time frame: at postoperative 1 year
Any coronary intervention performed during follow-up due to the coronary artery disease
Time frame: at postoperative 1 year
acute myocardial infarction, coronary reintervention, and cardiac death including sudden death during follow-up
Contact information is provided by the study sponsor or research team.
Ho Young Hwang, MD, PhD
CONTACT
Suk Ho Sohn, MD
CONTACT
Ho Young Hwang
Other
Comparison Between the Saphenous Vein as Y-composite Graft Based on the Left Internal Thoracic Artery Versus Aortocoronary Conduit for Coronary Artery Bypass Grafting: A Prospective Randomized Controlled Trial
Acronym: CONFIG2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07720349
Arterial Occlusive Diseases, Arteriosclerosis
Arendal, Norway
View Trial DetailsNCT02038127
Arterial Occlusive Diseases, Arteriosclerosis
Chuncheon, Gangwon-do, South Korea
View Trial DetailsNCT07190690
Arterial Occlusive Diseases, Arteriosclerosis
Alicante, Spain
View Trial DetailsNCT05611307
ASCVD, Arterial Occlusive Diseases
Indianapolis, Indiana, United States
View Trial Details